Fusion proteins comprising an interleukin-2 mutein and an antigen-binding fragment to serum albumin, and compositions and uses thereof
A recombinant fusion protein with an interleukin-2 mutein and antigen-binding fragment targets IL-2Rαβγ on Treg cells, addressing safety and convenience issues in autoimmune disease treatments by selectively activating these cells, thus stabilizing the immune system.
JP2025536327APending Publication Date: 2025-11-05APRILBIO
Patent Information
- Application Number
- JP2025522500
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-10-19
- Filing Date
- 2023-10-19
- Publication Date
- 2025-11-05
Smart Images
Figure 2025536327000001_ABST
Abstract
A recombinant fusion protein, as well as compositions and uses thereof, is provided, which comprises an interleukin-2 mutein and an antigen-binding fragment for serum albumin. Due to its increased in vivo half-life, the recombinant fusion protein has the advantage of a relatively long administration cycle. Due to the selective activity of the recombinant fusion protein against regulatory T cells, the recombinant fusion protein can be effectively used for the treatment of various immune diseases and inflammatory neurological diseases, including inflammatory bowel disease and systemic lupus erythematosus. TIFF2025536327000083.tif71128
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
US11,773,176
Anti-serum albumin Fab-effector moiety fusion construct, and a method of preparing the construct
US9879077B2